It’s developing treatments for retinal diseases.
SAN JUAN CAPISTRANO, CA -- Allegro Ophthalmics LLC, an ophthalmic biopharmaceutical company, has named Vicken Karageozian, MD, to the roles of CEO and president.
Hampar Karageozian, meanwhile, has been named executive chairman.
In his new role, Vicken Karageozian will prepare the company for its next milestone: entering Phase 3 clinical trials with its lead compound, risuteganib, in diabetic macular edema. He'll also continue developing risuteganib for other retinal disease indications, according to a press release.
"I would like to thank Hampar for his passion, dedication and the effort he has put forth the last seven years in the development of a potential first-in-class drug for the treatment of DME," said William J. Link, PhD, co-founder and managing director of Versant Ventures and member of Allegro’s Board of Directors. "His many years in drug discovery, and long track record of building successful ophthalmic companies have been essential for establishing a strong foundation for Allegro’s growth,”
"I am convinced that Vicken’s strategic vision, clinical development expertise and experience working with private and institutional investors will position Allegro for future success."
In his new role as executive chairman, Hampar Karageozian "will continue to drive Allegro’s strategic vision, focusing on new product discovery, research and development," according to the release.
"Vicken is a passionate leader focused on preparing the company for an important new milestone in its history," said Hampar Karageozian. "The Board and I are confident that with Vicken and his experienced management team, Allegro is well-positioned to bring risuteganib to market and provide a potential new treatment option for those patients with retinal diseases who respond poorly to the current standard of care."
Vicken Karageozian has more than 25 years’ experience building, leading and raising capital for companies in the ophthalmic pharmaceutical space. An ophthalmic surgeon by training and prior managing partner of Clarity Eye Group, he is the co-founder of three ophthalmic biotech companies, including ISTA Pharmaceuticals Inc., Vitreoretinal Technologies Inc. and Allegro. He is the inventor or co-inventor of numerous ophthalmic products with 82 patents issued or pending primarily on drug discoveries. In addition, he has been instrumental in raising more than $200 million in venture and institutional capital, corporate partnerships and regional licenses.